$25.00
Manufacturer: Poland
Symptomatic treatment of brain and dental pain, dysmenorrhea (periodic menstrual pain), neuralgia, back pain, joint pain, muscle pain, rheumatic pain, as well as cold and flu symptoms.
Description
IBUPROM №12 COMPOSITION
active substance: 1 tablet contains ibuprofen 400 mg
excipients: core: lactose monohydrate, povidone, starch corn talc sodium croscarmellose magnesium stearate silicon dioxide colloidal
shell: sucrose, talc, corn starch, titanium dioxide (E 171), carnauba wax, white wax.
IBUPROM №12 DOSAGE FORM
Film-coated tablets.
IBUPROM №12 MAIN PHYSICAL AND CHEMICAL PROPERTIES
white, oblong, sugar-coated tablets convex on both sides.
PHARMACOLOGICAL GROUP
Non-steroidal anti-inflammatory drugs ATX code M01A E01.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics.
Ibuprofen is an NSAID (NSAID) derivative of propionic acid that targets pain, fever and inflammation by inhibiting the synthesis of prostaglandins, which mediate pain and inflammation. In addition, ibuprofen reversibly inhibits platelet aggregation.
Pharmacokinetics.
Ibuprofen is well absorbed in the gastrointestinal tract and binds to blood plasma proteins. The onset of therapeutic action in symptomatic treatment appears within 15-30 minutes after administration. The maximum concentration in serum is determined 45 minutes after application (in the case of fasting). When this drug is taken with meals, peak levels are observed 1-2 hours after ingestion. Ibuprofen is metabolized in the liver, excreted by the kidneys unchanged or as metabolites. The half-life is about 2:00. In elderly patients, there are no significant differences in the pharmacokinetic profile.
INDICATIONS
Symptomatic treatment of headache, including migraine, toothache, dysmenorrhea (menstrual pain), neuralgia, back pain, joint pain, muscle pain, rheumatic pain, and symptoms of colds and flu.
CONTRAINDICATIONS
Hypersensitivity to ibuprofen or to any of the components of the drug. Hypersensitivity reactions (for example, asthma, rhinitis, angioedema or urticaria), which were previously observed after the use of ibuprofen, acetylsalicylic acid or other NSAIDs.
Peptic ulcer / active bleeding or a history of relapses (two or more severe episodes of peptic ulcer or bleeding).
Gastrointestinal bleeding or perforation associated with a history of NSAIDs.
The use of the drug with concomitant NSAIDs, including specific inhibitors of cyclooxygenase-2.
Severe dysfunction of the liver, kidney, heart failure.
Cerebrovascular or other bleeding.
Hematopoiesis or blood clotting disorders.
Recent Reviews